Total for the last 12 months
number of access : ?
number of downloads : ?
ID 118971
Author
Bando, Hiroshi Tokushima University|Medical Research KAKEN Search Researchers
Keywords
Astaxanthin
Anti-aging medicine
oral hypoglycemic agent
Imeglimin
Content Type
Journal Article
Description
Latest Standards of Medical Care in Diabetes-2022 was presented from American Diabetes Association (ADA) on Jan 2022. A topic of Oral Hypoglycemic Agent (OHA) has been imeglimin. It may work through multiple action mechanism such as increasing insulin secretion, decreasing β-cell dysfunction, and preventing death of epithelial cells. Clinically, it decreases HbA1c by 0.5-1.0% for 1000mg twice a day. Diabetes and anti-aging medicine have common background pathophysiologically. Astaxanthin (AX) is the nephroprotective as mitochondrial regulator. AX-functioning mechanism includes to ameliorate insulin resistance and glucose intolerance. Imeglimin normalizes insulin sensitivity and glucose tolerance with maintaining mitochondrial function, suggesting common mechanism.
Journal Title
Edelweiss Journal of Biomedical Research and Review
ISSN
26902613
Publisher
Edelweiss Publications
Volume
4
Issue
1
Start Page
1
End Page
2
Published Date
2022-06-23
Rights
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
DOI (Published Version)
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences